June 06, 2023

Briquilimab has shown it is a safe and well-tolerated conditioning agent for older patients receiving an allogeneic hematopoietic cell transplantation.

May 25, 2023

Ellipses Pharma is a drug company that works to accelerate cancer treatment through innovative drug models.

March 05, 2023

Phase 2 of the KOMET-001 trial has dosed its first set of patients. This is a continuation of a trial testing the efficacy of Ziftomenib.

December 14, 2022

revumenib

December 12, 2022

The long-term follow-up of the VIALE-A study shows that venetoclax and azacitidine are better in terms of overall survival compared to azacitidine alone.

September 14, 2022

The FDA has cleared Curis to resume enrollment of patients in their Take Aim Leukemia study.

August 22, 2022

ABL602 is a bispecific antibody in early development that targets CLL-1, a molecule found in leukemia stem cells but is absent in normal stem cells.

July 27, 2022

CAR-T therapy targeting CD70 combined with azacitidine is development and so far has shown early promising results.

July 05, 2022

Dr. Ravandi, an AML expert from MD Anderson discusses his trial evaluating the use of an oral form of decitabine in combination with venetoclax. 

July 04, 2022

Dr. Stein discusses his two posters at the EHA annual congress evaluating tamibarotene and lanraplenib (LANRA), two new drugs in development for AML.